Visiongain’s latest report, Pre-Filled Syringes Market Report 2026-2036, provides detailed forecasts and strategic analysis across material, delivery, design, type, application, and end-user segments, including technology trends, trade and supply chain dynamics, and competitive positioning.

The global pre-filled syringes market is valued at US$9.21 billion in 2026 and is projected to reach US$22.18 billion by 2036, at a CAGR of 9.2% during the forecast period. Growth is driven by the continued expansion of biologic and biosimilar therapies, rising demand for patient-centric self-administration formats, and increasing pharmaceutical investment in advanced fill-finish capacity and connected drug delivery systems.

Key Market Insights

• The global pre-filled syringes market will reach US$22.18 billion by 2036, growing at a CAGR of 9.2%
• Growth is driven by biologics expansion, patient-centric care models, and innovation in drug delivery technologies
• Key regions: North America, Europe, Asia Pacific
• Leading companies: Becton Dickinson, Gerresheimer, SCHOTT AG, Stevanato Group, West Pharmaceutical Services
• Key trend: Transition toward ready-to-use, connected, and large-volume injectable delivery platforms supporting homecare and self-administration

Download Sample Request

Market Drivers

Increasing Approval of Biologic Therapies

The increasing approval and commercialisation of biologic therapies is a major factor supporting demand for pre-filled syringes. Biologics require highly controlled administration due to complex molecular structures, sensitivity to contamination, and strict dosing requirements. Pre-filled syringes address these challenges by providing sterile, pre-measured, and ready-to-administer delivery formats that improve convenience while supporting safer administration. Their importance is growing across oncology, autoimmune diseases, rare disorders, and metabolic conditions, where long-term injectable treatment is common.

Recent approvals reinforcing injectable biologics growth include Amvuttra (vutrisiran) for transthyretin-mediated amyloidosis-related cardiomyopathy in March 2025, Lumakras in combination with Vectibix for advanced colorectal cancer in January 2025, and Alhemo (concizumab-mtci) for haemophilia management in December 2024, each highlighting the sustained growth of specialised injectable therapies across the biologics pipeline.

Innovation in Drug Delivery Systems

Advances in syringe materials, device engineering, and fill-finish technologies are strengthening the performance and commercial viability of pre-filled syringes. The integration of digital health technologies is also creating new growth opportunities, with smart pre-filled syringes and connected autoinjector systems enabling real-time monitoring of drug administration, supporting treatment adherence and patient oversight in chronic disease management.

In January 2026, Ypsomed announced advancements in connected autoinjector platforms compatible with pre-filled syringes and integrated digital health ecosystems. In January 2026, Gerresheimer expanded its polymer-based ready-to-fill syringe portfolio to support sensitive biologics and mRNA-based therapies. In October 2025, SCHOTT Pharma commercially launched its 5.5 mL prefillable staked-needle glass syringe for compatibility with Ypsomed’s large-volume autoinjector platform, supporting self-administration in homecare settings.

Technology & Innovation

Large-Volume and Combination Product Development

Manufacturers are expanding product capabilities to address the growing requirements of large-volume biologics and integrated drug-device combination products. Advanced syringe platforms are being developed to support high-dose therapies, extended-release formulations, and subcutaneous delivery of complex molecules, improving scalability while maintaining dosing precision and product integrity. These developments are enabling pharmaceutical companies to accelerate the transition of biologic products from traditional vial formats into pre-filled syringe and autoinjector presentations.

In 2024, Stevanato Group expanded its EZ-fill platform to support pre-sterilised, ready-to-use pre-filled syringes, enabling improved scalability and faster production readiness for pharmaceutical companies, reflecting the broader industry emphasis on manufacturing flexibility and reduced time-to-market for injectable therapies.

Trade & Supply Chain Dynamics

U.S. trade tariffs on medical devices, pharmaceutical components, and imported raw materials are increasing cost pressures across the global pre-filled syringes market, particularly for supply chains reliant on manufacturing hubs in Asia and parts of Europe. Critical inputs including pharmaceutical-grade glass, specialised polymers, elastomer components, and stainless-steel needles are sourced through complex international supplier networks, creating exposure to import-related cost escalation.

Smaller manufacturers and CDMOs are especially vulnerable due to lower purchasing power and reduced flexibility in supplier negotiations. In response, companies are strengthening regional supply networks, expanding domestic fill-finish capabilities, and reducing dependence on single-country sourcing to improve operational resilience.

Commercial Impact

• Cost pressure: Tariffs on pharmaceutical inputs and precision components are affecting procurement economics, manufacturing margins, and pricing structures, particularly in high-volume biologics and injectable segments
• Supply chain shifts: Companies are diversifying supplier networks, expanding North American manufacturing infrastructure, and strengthening collaboration with contract manufacturing partners to reduce tariff exposure
• Margin implications: Rising input and compliance costs are increasing capital requirements for manufacturers investing in regional capacity and alternative material strategies
• Competitive positioning: Organisations with diversified supply networks and vertically integrated fill-finish capabilities are better positioned to manage cost volatility and maintain procurement competitiveness

Market Opportunities

Rapid Expansion of Biologics and Biosimilars

The continued expansion of biologics and biosimilars is creating significant growth opportunities for the pre-filled syringes market. Pharmaceutical companies and healthcare providers are increasingly transitioning biologic products from vial presentations toward pre-filled syringe and autoinjector formats to improve operational efficiency, treatment convenience, and patient adherence. In December 2025, Samsung Bioepis received a positive opinion from the European Medicines Agency for the pre-filled syringe presentation of BYOOVIZ (ranibizumab), with commercialisation expected in 2026, reflecting the broader industry shift toward integrated injectable delivery formats.

Rising Demand for Ready-to-Use Injectable Drug Formats

Healthcare providers are placing greater emphasis on delivery formats that improve workflow efficiency, reduce preparation time, and minimise administration-related errors, particularly within high-volume clinical environments. Pre-filled syringes provide sterile, ready-to-use delivery systems that improve operational consistency while reducing drug wastage and handling complexity. Market opportunities are being reinforced by rising demand for speciality injectable therapies, biologics, and clinical trial products that require standardised dosing and reliable administration, with pharmaceutical manufacturers investing in ready-to-use packaging technologies and advanced fill-finish capabilities to accelerate commercialisation timelines.

Competitive Landscape

The major players operating in the pre-filled syringes market include Amsino International, AptarGroup, B. Braun SE, Baxter International, Becton Dickinson, Biocon, Cardinal Health, Catalent, Credence MedSystems, Datwyler, Debiotech, Elcam Medical, Fresenius Kabi, Gerresheimer, Jiangsu Micsafe Medical Technology, Nipro, Owen Mumford, SHL Medical, SCHOTT AG, Stevanato Group, Terumo, Vetter, Weigao Medical International, and West Pharmaceutical Services.

These companies are strengthening their market positions through M&A, R&D investment, strategic collaborations, regional manufacturing expansion, and new product launches, with increasing focus on advanced delivery platforms and fill-finish capabilities for complex biologics.

Recent Developments

• January 2026 – BD announced a US$110 million investment to bring BD Neopak Glass Prefillable Syringe production to its Columbus, Nebraska facility, with US$100 million allocated to establishing the Neopak line and US$10 million to enhance cannula manufacturing; supply is expected to begin in mid-2026 and approximately 120 new jobs will be created
• January 2026 – Vetter acquired a 95-acre industrial site in Saarlouis, Germany, for the development of a new state-of-the-art injectable drug production facility
• January 2026 – Amsino International and Partners Cooperative entered into a three-year partnership to give Cooperative members access to Amsino’s pre-filled saline flush syringe products, ensuring supply continuity and long-term value for patient care

Frequently Asked Questions

What is driving growth in the pre-filled syringes market?

Growth is driven by the expansion of biologic and biosimilar therapies, rising demand for patient-centric self-administration formats, and increasing pharmaceutical investment in advanced fill-finish capacity and connected drug delivery systems.

How are trade and supply chain dynamics affecting the market?

U.S. tariffs on medical devices and pharmaceutical components are increasing production costs and affecting procurement economics, particularly for manufacturers reliant on international supply chains. This is accelerating regionalisation of manufacturing and investment in domestic fill-finish capability across North America.

Who are the leading companies in the market?

Key players include Becton Dickinson, Gerresheimer, SCHOTT AG, Stevanato Group, West Pharmaceutical Services, and Vetter.

Download Sample Request

Related Reports

Cell & Gene Therapy Market Report 2026-2036

Decentralised Clinical Trials Market Report 2026-2036

Vaccine Contract Manufacturing Market Report 2026-2036

About Visiongain

Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.

Media Contact

press@visiongain.com
+44 (0)20 7336 6100
www.visiongain.com